These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

583 related items for PubMed ID: 28403877

  • 1. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.
    Cha SA, Park YM, Yun JS, Lim TS, Song KH, Yoo KD, Ahn YB, Ko SH.
    Lipids Health Dis; 2017 Apr 13; 16(1):58. PubMed ID: 28403877
    [Abstract] [Full Text] [Related]

  • 2. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.
    Persson F, Nyström T, Jørgensen ME, Carstensen B, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Eriksson JW, Norhammar A, Bodegard J, Birkeland KI.
    Diabetes Obes Metab; 2018 Feb 13; 20(2):344-351. PubMed ID: 28771923
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The EMPA-REG study: What has it told us? A diabetologist's perspective.
    DeFronzo RA.
    J Diabetes Complications; 2016 Feb 13; 30(1):1-2. PubMed ID: 26541076
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I.
    Endocr Pract; 2017 Jul 13; 23(7):831-840. PubMed ID: 28332871
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Wang Z, Sun J, Han R, Fan D, Dong X, Luan Z, Xiang R, Zhao M, Yang J.
    Diabetes Obes Metab; 2018 Jan 13; 20(1):113-120. PubMed ID: 28656707
    [Abstract] [Full Text] [Related]

  • 8. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study.
    Hiruma S, Shigiyama F, Hisatake S, Mizumura S, Shiraga N, Hori M, Ikeda T, Hirose T, Kumashiro N.
    Cardiovasc Diabetol; 2021 Feb 02; 20(1):32. PubMed ID: 33530982
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR).
    Fuchigami A, Shigiyama F, Kitazawa T, Okada Y, Ichijo T, Higa M, Hiyoshi T, Inoue I, Iso K, Yoshii H, Hirose T, Kumashiro N.
    Cardiovasc Diabetol; 2020 Jan 07; 19(1):1. PubMed ID: 31910850
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study.
    Shigiyama F, Kumashiro N, Fuchigami A, Hirose T.
    Cardiovasc Diabetol; 2018 Jun 12; 17(1):86. PubMed ID: 29895330
    [Abstract] [Full Text] [Related]

  • 15. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives.
    Gokhale M, Buse JB, Jonsson Funk M, Lund J, Pate V, Simpson RJ, Stürmer T.
    Diabetes Obes Metab; 2017 Jul 12; 19(7):970-978. PubMed ID: 28195389
    [Abstract] [Full Text] [Related]

  • 16. DECLARE-TIMI 58: Participants' baseline characteristics.
    Raz I, Mosenzon O, Bonaca MP, Cahn A, Kato ET, Silverman MG, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Langkilde AM, Johansson PA, Sabatine MS, Wiviott SD.
    Diabetes Obes Metab; 2018 May 12; 20(5):1102-1110. PubMed ID: 29322605
    [Abstract] [Full Text] [Related]

  • 17. Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.
    Deacon CF, Lebovitz HE.
    Diabetes Obes Metab; 2016 Apr 12; 18(4):333-47. PubMed ID: 26597596
    [Abstract] [Full Text] [Related]

  • 18. Effects of Concomitant Administration of a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Showing Relatively Good Glycemic Control Under Treatment with a Sodium Glucose Co-Transporter 2 Inhibitor.
    Kusunoki M, Natsume Y, Miyata T, Tsutsumi K, Oshida Y.
    Drug Res (Stuttg); 2018 Dec 12; 68(12):704-709. PubMed ID: 29966149
    [Abstract] [Full Text] [Related]

  • 19. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
    Zhou FL, Watada H, Tajima Y, Berthelot M, Kang D, Esnault C, Shuto Y, Maegawa H, Koya D.
    Diabetes Obes Metab; 2019 Aug 12; 21(8):1925-1934. PubMed ID: 31050099
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
    Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Watanabe Y, Gouda M, Iijima H.
    Diabetes Obes Metab; 2018 Jan 12; 20(1):77-84. PubMed ID: 28608617
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.